Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
J Gastroenterol Hepatol
    October 2025
  1. FAN C, He X, Zhou Y, Ye C, et al
    The Effects of CD100 Stimulation on Primary Human Hepatocytes (PHHs) and Its Implications in HBV-Related Liver Cirrhosis.
    J Gastroenterol Hepatol. 2025 Oct 21. doi: 10.1111/jgh.70123.
    >> Share

  2. AGARWAL A, Pachisia AV, Agarwal S, Mehta S, et al
    Celiac Disease and Its Impact on Liver-Related Outcomes in Patients With All-Cause Cirrhosis: The CELIHEP Study.
    J Gastroenterol Hepatol. 2025 Oct 16. doi: 10.1111/jgh.70082.
    >> Share

  3. XU L, Liu J
    Comment on Impact of Renin-Angiotensin-Aldosterone System Inhibitors on Liver-Related Events and Mortality in Patients With Cirrhosis: A Meta-Analysis of Real-World Evidence.
    J Gastroenterol Hepatol. 2025 Oct 16. doi: 10.1111/jgh.70114.
    >> Share

  4. KO KA, Oh H, Kim MS, Hong HP, et al
    Role of ALBI Grade as a Predictive Factor for Long-Term Mortality in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
    J Gastroenterol Hepatol. 2025 Oct 3. doi: 10.1111/jgh.70098.
    >> Share

  5. ZENG X, Li Z, Chen Y, Yao H, et al
    Impairing Islets in Newborn Mice Promotes Liver Fibrosis and Carcinoma Development in a Rapid NASH Model.
    J Gastroenterol Hepatol. 2025;40:2601-2612.
    >> Share

  6. VIJAYALEKSHMI B, Chaudhary A, Prabhu SB, Sharma A, et al
    Plasma-Driven Monocyte Dysfunction Drives Disease Progression in Alcohol-Related Acute-on-Chronic Liver Failure.
    J Gastroenterol Hepatol. 2025;40:2591-2600.
    >> Share

  7. KIM MN, Park GU, You SC, Lee JS, et al
    Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis.
    J Gastroenterol Hepatol. 2025 Oct 1. doi: 10.1111/jgh.70078.
    >> Share

    September 2025
  8. MAESAKA K, Hikita H, Kai M, Tahata Y, et al
    Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2025 Sep 9. doi: 10.1111/jgh.70068.
    >> Share

  9. ZHANG Y, Jiang L, Jiang Y, Zhu L, et al
    Elevated HSP70 Ameliorates Liver Failure Patients via Its Novel Natural Inhibitor.
    J Gastroenterol Hepatol. 2025;40:2300-2310.
    >> Share

  10. KUO CH, El-Omar E, Kao CY, Lin JT, et al
    Compositional and Metabolomic Shifts of the Gut Microbiome in Alcohol-Related Liver Disease.
    J Gastroenterol Hepatol. 2025;40:2176-2189.
    >> Share

  11. EZHILARASAN D
    Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?
    J Gastroenterol Hepatol. 2025;40:2163-2175.
    >> Share

    August 2025
  12. KARATAYLI SC, Weber SN, Hall RA, Hohl M, et al
    Hepatic Inflammation and Liver Injury in a Model of Bacterial Infection Triggered Acute-on-Chronic Liver Injury.
    J Gastroenterol Hepatol. 2025 Aug 17. doi: 10.1111/jgh.70055.
    >> Share

  13. HEGAZY RA
    Unraveling Liver Cirrhosis: Bridging Pathophysiology to Innovative Therapeutics.
    J Gastroenterol Hepatol. 2025 Aug 3. doi: 10.1111/jgh.70037.
    >> Share

  14. CHEN YX, Wu YP, Zhang Y, Ji PX, et al
    Modulation of Lipid Metabolism and Keap1-Nrf2 Pathway Activation in Macrophages by Targeting PPARgamma Affects NAFLD Progression.
    J Gastroenterol Hepatol. 2025;40:2119-2133.
    >> Share

  15. DANPANICHKUL P, Thongprayoon C, Suparan K, Kim D, et al
    Evolving Public Attention to Steatotic Liver Disease: A 20-Year Analysis (2004-2024): Surging Steatotic Liver Disease Focus.
    J Gastroenterol Hepatol. 2025;40:2053-2059.
    >> Share

  16. LIU Z, Liu L, Liu S, Ba Y, et al
    Genome-Scale CRISPR-Cas9 Analysis Reveals Tumor Heterogeneity and Identifies NDC80 as Novel Biomarker in HCC.
    J Gastroenterol Hepatol. 2025;40:2078-2090.
    >> Share

  17. HATANAKA T, Kakizaki S, Hiraoka A, Tada T, et al
    Comparison of Surgical Resection and Radiofrequency Ablation for Early-Stage HCC Patients With Child-Pugh Class B.
    J Gastroenterol Hepatol. 2025;40:2068-2077.
    >> Share

  18. GHANI L, Aboona MB, Faulkner CS, Rangan P, et al
    Increased Mortality Among Lean Versus Non-Lean Adults With MASLD: A Multicenter Study.
    J Gastroenterol Hepatol. 2025;40:1919-1925.
    >> Share

    July 2025
  19. CHEN Y, Zhai D, Shen J, Hu W, et al
    Impact of Renin-Angiotensin-Aldosterone System Inhibitors on Liver-Related Events and Mortality in Patients With Cirrhosis: A Meta-Analysis of Real-World Evidence.
    J Gastroenterol Hepatol. 2025 Jul 26. doi: 10.1111/jgh.70003.
    >> Share

  20. LIU C, Chen G, Liao J, Wu D, et al
    m6A Modification-Mediated Regulation of DCAF13 Promotes Glycolytic Metabolism and Drives Hepatocellular Carcinoma Progression via Interaction With G6PD.
    J Gastroenterol Hepatol. 2025 Jul 25. doi: 10.1111/jgh.70015.
    >> Share

  21. JANG TY, Wang CW, Liang PC, Wei YJ, et al
    Steatotic Liver Disease-Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog-Treated Chronic Hepatitis B.
    J Gastroenterol Hepatol. 2025 Jul 24. doi: 10.1111/jgh.70021.
    >> Share

  22. KIM YJ, Kim JW
    HDAC9 as a Sex-Dependent Epigenetic Driver of Hepatic Steatosis and Adipose Inflammation.
    J Gastroenterol Hepatol. 2025 Jul 24. doi: 10.1111/jgh.70029.
    >> Share

  23. SUN R, Wang X, Ma J, Cai Y, et al
    The Roles and Clinical Significance of Major Hepatic-Derived Metabolites in Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2025 Jul 19. doi: 10.1111/jgh.70008.
    >> Share

    June 2025
  24. CAINES A, Lu M, Wu T, Trudeau S, et al
    Pre-Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis.
    J Gastroenterol Hepatol. 2025 Jun 23. doi: 10.1111/jgh.17035.
    >> Share

  25. WANG L, Zhao Y, Duan B, Wang Y, et al
    Iron Quantification Using Spectral CT-Based Material Decomposition Technique for Noninvasive Hepatic Fibrosis Staging: An Experimental Study.
    J Gastroenterol Hepatol. 2025 Jun 4. doi: 10.1111/jgh.17031.
    >> Share

  26. GUO X, Wu L, Lai J, Wu Y, et al
    Causal Associations Between Lipids, NPC1L1, and Liver Cancer Risk: Insights From Mendelian Randomization and Bioinformatics.
    J Gastroenterol Hepatol. 2025;40:1602-1615.
    >> Share

  27. XIA Y, Tie J, Wang G, Wu H, et al
    Benefits of TIPS for Patients With Large Ascites Preceding Recurrent or Refractory ascites: A Multicenter Cohort Study.
    J Gastroenterol Hepatol. 2025;40:1574-1585.
    >> Share

    May 2025
  28. NIIZEKI T, Mawatari S, Shibata M, Sasaki R, et al
    Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First-Line Therapy for Intermediate-Stage Hepatocellular Carcinoma Beyond the Up-to-Seven Criteria.
    J Gastroenterol Hepatol. 2025 May 31. doi: 10.1111/jgh.17024.
    >> Share

  29. WANG J, Gao J, Zhang Q, Lu J, et al
    Ileal FXR Knockdown Ameliorates MASLD Progression in Rats via Modulating Bile Acid Metabolism Mediated by Gut Microbiota.
    J Gastroenterol Hepatol. 2025 May 24. doi: 10.1111/jgh.17017.
    >> Share

  30. MATSUBARA Y, Tsuboi A, Shigenobu S, Hirata I, et al
    Clinical Significance of Small-Bowel Mucosal Changes in Liver Cirrhosis Patients With Suspected Small-Bowel Bleeding: A Capsule Endoscopy Study.
    J Gastroenterol Hepatol. 2025 May 19. doi: 10.1111/jgh.17002.
    >> Share

  31. JOSHI A, Raja HAA, Roy P, Latif F, et al
    Comparison of Carvedilol to Propranolol in Reduction of Hepatic Venous Pressure Gradient in Liver Cirrhosis: A Meta-Analysis.
    J Gastroenterol Hepatol. 2025 May 19. doi: 10.1111/jgh.16999.
    >> Share

  32. QIN J, Zhu W, Zhou W
    Navigating the Paradox of IL-22: Friend or Foe in Hepatic Health?
    J Gastroenterol Hepatol. 2025 May 13. doi: 10.1111/jgh.16991.
    >> Share

  33. LIOU WL, Tan SY, Yamada H, Krishnamoorthy T, et al
    Performance of the GALAD Model in an Asian Cohort Undergoing Hepatocellular Carcinoma Surveillance: A Prospective Cohort Study.
    J Gastroenterol Hepatol. 2025 May 10. doi: 10.1111/jgh.16997.
    >> Share

  34. DONG L, Zhang H, Kang Y, Wang F, et al
    NLRP3 and Gut-Liver Axis: New Possibility for the Treatment of Alcohol-Associated Liver Disease.
    J Gastroenterol Hepatol. 2025;40:1070-1078.
    >> Share

  35. FUKAMIZO K, Hagiwara Y, Kimura T, Matsuyama Y, et al
    Individualized Effects of Weight Gain in Adulthood on the Development of MASLD in Japanese Non-Obese Individuals.
    J Gastroenterol Hepatol. 2025;40:1255-1262.
    >> Share

  36. CHANG YW, Kuo CN, Chang CL, Hsu JC, et al
    Sequential Treatment of Metastatic Colorectal Cancer in Taiwan: Real-World Evidence From Regorafenib and Trifluridine/Tipiracil Use.
    J Gastroenterol Hepatol. 2025;40:1135-1142.
    >> Share

    April 2025
  37. TAMAKI N, Huang DQ, Lee HW, Park SY, et al
    Head-to-Head Comparison of Long-Term HCC Risk of Antivirals-Treated Versus Untreated Low-Level Viremia in HBV-Compensated Cirrhosis.
    J Gastroenterol Hepatol. 2025 Apr 27. doi: 10.1111/jgh.16986.
    >> Share

  38. LEE HA, Lee HW, Seo YS, Sinn DH, et al
    Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy-Induced HBsAg Seroclearance.
    J Gastroenterol Hepatol. 2025 Apr 24. doi: 10.1111/jgh.16973.
    >> Share


  39. Correction to "PLK2 Inhibited Oxidative Stress and Ameliorated Hepatic Ischemia-Reperfusion Injury Through Phosphorylating GSK3beta".
    J Gastroenterol Hepatol. 2025 Apr 10. doi: 10.1111/jgh.16966.
    >> Share

  40. FILHO VOC, Passos PRC
    PCED1A as a Predictive Biomarker for Immunotherapy and Anti-Angiogenic Treatment in Hepatocellular and Colorectal Cancer.
    J Gastroenterol Hepatol. 2025 Apr 9. doi: 10.1111/jgh.16969.
    >> Share

  41. LI J, Zhao Y, Wang Z, Ma A, et al
    Irisin Alleviates Impaired Mitochondrial Fusion via Enhancing PKA/SIRT3/mTOR Pathway in Hepatic Steatosis.
    J Gastroenterol Hepatol. 2025 Apr 2. doi: 10.1111/jgh.16950.
    >> Share

  42. PARK SH, Song SJ, Lee JA, Shin JA, et al
    Effects of Aging on the Severity of Liver Injury in Mice With Iron Overload.
    J Gastroenterol Hepatol. 2025;40:1016-1025.
    >> Share

  43. MATONO T, Tada T, Kumada T, Hiraoka A, et al
    Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCC.
    J Gastroenterol Hepatol. 2025;40:949-959.
    >> Share

  44. ZHAO N, Wang H, Zhang M, Tian W, et al
    Characterization of NK Cells Using Single-Cell RNA Sequencing in Patients With Acute-On-Chronic Liver Failure.
    J Gastroenterol Hepatol. 2025;40:917-929.
    >> Share

  45. ZHAI X, He X, Huang A, Liu Z, et al
    Analysis of Immunometabolic Profiles in Patients With Chronic Drug-Induced Liver Injury and Validation in Mice to Reveal Potential Mechanisms.
    J Gastroenterol Hepatol. 2025;40:987-1003.
    >> Share

    March 2025

  46. Correction to 'Cirrhosis in primary practice: many patients remain potentially undiagnosed and are not receiving liver cancer surveillance'.
    J Gastroenterol Hepatol. 2025 Mar 14. doi: 10.1111/jgh.16918.
    >> Share

  47. TAO Q, Zhou Y, Chen G, Sun J, et al
    Cisplatin Promotes Hepatotoxicity by cGAS-STING Mediated Innate Immune Response.
    J Gastroenterol Hepatol. 2025 Mar 7. doi: 10.1111/jgh.16926.
    >> Share

  48. JAFARI-KHORCHANI M, Pantopoulos K, Zare-Mehrjardi MJ, Allameh A, et al
    Sequential Changes in NOX4 Expression, Oxidative Stress Indices, PIIINP, and Liver Histopathology During Hepatocellular Carcinogenesis Induced in Mice.
    J Gastroenterol Hepatol. 2025 Mar 3. doi: 10.1111/jgh.16914.
    >> Share

    February 2025
  49. GIRI S, Ingawale S, Khatana G, Gore P, et al
    Metabolic Cause of Cirrhosis Is the Emerging Etiology for Primary Liver Cancer in the Asia-Oceania Region: Analysis of Global Burden of Disease (GBD) Study 2021.
    J Gastroenterol Hepatol. 2025 Feb 27. doi: 10.1111/jgh.16922.
    >> Share

  50. LIAO C, Zhang Y, Yang J, Wang S, et al
    Single-Cell Transcriptomic Analysis Reveals an Aggressive Basal-Like Tumor Cell Subpopulation Associated With Poor Prognosis in Intrahepatic Cholangiocarcinoma.
    J Gastroenterol Hepatol. 2025 Feb 24. doi: 10.1111/jgh.16915.
    >> Share

  51. EZHILARASAN D
    Thyromimetics and MASLD: Unveiling the Novel Molecules Beyond Resmetirom.
    J Gastroenterol Hepatol. 2025;40:367-378.
    >> Share

  52. SINGH SP, Bhatia V, Kale P, Kumar G, et al
    Bowel Colonization With Carbapenem-Resistant Bacteria Is Associated With Short-Term Outcomes in Patients With Acute-On-Chronic Liver Failure.
    J Gastroenterol Hepatol. 2025;40:528-536.
    >> Share

    January 2025
  53. ANG TL, Hang DV, Li JW, Ho JCL, et al
    APAGE Position Statements on Green and Sustainability in Gastroenterology, Hepatology, and Gastrointestinal Endoscopy.
    J Gastroenterol Hepatol. 2025 Jan 31. doi: 10.1111/jgh.16896.
    >> Share

  54. PENG J, Zhang L, Dong Y, Long W, et al
    Factors Influencing Liver Cirrhosis Progression in Wilson's Disease Patients: A Retrospective Cohort Study Over 5 Years.
    J Gastroenterol Hepatol. 2025 Jan 31. doi: 10.1111/jgh.16889.
    >> Share

  55. SONG BG, Park G, Goh MJ, Kang W, et al
    A Risk Prediction Model for Hepatocellular Carcinoma in the General Population Without Traditional Risk Factors for Liver Disease.
    J Gastroenterol Hepatol. 2025 Jan 29. doi: 10.1111/jgh.16893.
    >> Share

  56. SHIN SK, Mishima Y, Lee Y, Kwon OS, et al
    Current Landscape of Adoptive Cell Therapy and Challenge to Develop "Off-The-Shelf" Therapy for Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2025 Jan 26. doi: 10.1111/jgh.16872.
    >> Share

  57. WANG M, Zhang Q, Wang J
    Expression of PCED1A in Hepatocellular Carcinoma and Colorectal Cancer and Its Relationship with Immune Infiltration: Potential as a Diagnostic Marker.
    J Gastroenterol Hepatol. 2025 Jan 26. doi: 10.1111/jgh.16890.
    >> Share

  58. REN X, Wu Y, Song T, Yang Q, et al
    Clonorchis sinensis Promotes Intrahepatic Cholangiocarcinoma Progression by Activating FASN-Mediated Fatty Acid Metabolism.
    J Gastroenterol Hepatol. 2025 Jan 13. doi: 10.1111/jgh.16879.
    >> Share

  59. ZHAO Y, Zhu W, Dong S, Zhang H, et al
    Glucose Metabolism Reprogramming of Immune Cells in the Microenvironment of Pancreatic and Hepatobiliary Cancers.
    J Gastroenterol Hepatol. 2025 Jan 8. doi: 10.1111/jgh.16873.
    >> Share

  60. HATANAKA T, Kakizaki S, Hiraoka A, Tada T, et al
    Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models.
    J Gastroenterol Hepatol. 2025 Jan 6. doi: 10.1111/jgh.16871.
    >> Share

  61. KIM A, Kang D, Choi SC, Sinn DH, et al
    Cardiometabolic risk factors and coronary atherosclerosis progression in patients with metabolic dysfunction-associated steatotic liver disease: the influential role of quantity over type.
    J Gastroenterol Hepatol. 2025;40:258-264.
    >> Share

  62. GUPTA P, Hsu YC, Liang LL, Chu YC, et al
    Automatic localization and deep convolutional generative adversarial network-based classification of focal liver lesions in computed tomography images: A preliminary study.
    J Gastroenterol Hepatol. 2025;40:166-176.
    >> Share

  63. TAMURA Y, Saeki C, Kanai T, Kiryu S, et al
    Comparison of the ability between dual-energy X-ray absorptiometry and bioelectrical impedance analysis for diagnosing low skeletal muscle mass and sarcopenia in patients with chronic liver disease.
    J Gastroenterol Hepatol. 2025;40:274-281.
    >> Share

  64. VAZ K, Kemp W, Majeed A, Lubel J, et al
    Validation of serum non-invasive tests of liver fibrosis as prognostic markers of clinical outcomes in people with fatty liver disease in Australia.
    J Gastroenterol Hepatol. 2025;40:241-249.
    >> Share

  65. CUI XS, Li HZ, Li L, Xie CZ, et al
    Rodent model of metabolic dysfunction-associated fatty liver disease: a systematic review.
    J Gastroenterol Hepatol. 2025;40:48-66.
    >> Share

    December 2024
  66. HU S, Kang H, Bae M, Kim MB, et al
    Histone Deacetylase 9 Deletion Inhibits Hepatic Steatosis and Adipose Tissue Inflammation in Male Diet-Induced Obese Mice.
    J Gastroenterol Hepatol. 2024 Dec 27. doi: 10.1111/jgh.16856.
    >> Share

  67. KOH HH, Kang M, Kim DG, Park JH, et al
    Comparative Validation of Prediction Models for HCC Outcomes in Living Donor Liver Transplantation: Superiority of Tumor Markers to Imaging Study.
    J Gastroenterol Hepatol. 2024 Dec 26. doi: 10.1111/jgh.16857.
    >> Share

  68. SALEEPOL A, Chulroek T, Vimonsuntirungsri T, Luangsukrerk T, et al
    Gastrointestinal: Direct Visualization of Biliary Tuberculosis.
    J Gastroenterol Hepatol. 2024 Dec 11. doi: 10.1111/jgh.16836.
    >> Share

  69. CHEN J, Chen X, Cai H, Yang Y, et al
    The ubiquitination degradation of KLF15 mediated by WSB2 promotes lipogenesis and progression of hepatocellular carcinoma via inhibiting PDLIM2 expression.
    J Gastroenterol Hepatol. 2024 Dec 5. doi: 10.1111/jgh.16812.
    >> Share

  70. WONG DN, Hui RW, Mak LY, Seto WK, et al
    Gastrointestinal: Biliary Obstruction From Hepatic Artery Aneurysms: Implications for Treatment Selection.
    J Gastroenterol Hepatol. 2024 Dec 4. doi: 10.1111/jgh.16841.
    >> Share

  71. NIKOLI A, Orfanidou M, Goulas A, Goulis DG, et al
    Circulating lipoprotein(a) in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024;39:2572-2581.
    >> Share

  72. MALANDRIS K, Arampidis D, Mainou M, Papadopoulos N, et al
    FibroScan-AST score for diagnosing fibrotic MASH: A systematic review and meta-analysis of diagnostic test accuracy studies.
    J Gastroenterol Hepatol. 2024;39:2582-2591.
    >> Share

  73. PAN L, Wang L, Ma H, Ding F, et al
    Relevance of combined influence of nutritional and inflammatory status on non-alcoholic fatty liver disease and advanced fibrosis: A mediation analysis of lipid biomarkers.
    J Gastroenterol Hepatol. 2024;39:2853-2862.
    >> Share

  74. US ALTAY D, Kaya Y, Mataraci Degirmenci D, Kocyigit E, et al
    Non-alcoholic fatty liver disease: The importance of physical activity and nutrition education-A randomized controlled study.
    J Gastroenterol Hepatol. 2024;39:2723-2734.
    >> Share

  75. TENG X, Shang J, Du L, Huang W, et al
    RNA-binding protein Trx regulates alternative splicing and promotes metastasis of HCC via interacting with LINC00152.
    J Gastroenterol Hepatol. 2024;39:2892-2902.
    >> Share

  76. KIM K, Lee Y, Lee JS, Kim MN, et al
    Incidence of metabolic dysfunction-associated steatotic liver disease and advanced fibrosis and impact of overweight/obesity in elderly population: a nationwide cohort study.
    J Gastroenterol Hepatol. 2024;39:2845-2852.
    >> Share

  77. MORISHIMA S, Abe A, Okamoto S, Kapoor MP, et al
    Partially hydrolyzed guar gum suppresses binge alcohol-induced liver fat accumulation via gut environment modulation in mice.
    J Gastroenterol Hepatol. 2024;39:2700-2708.
    >> Share

  78. SUN F, Wang J, Ji X, Wang Z, et al
    CCL25 contributes to the pathogenesis of D-Gal/LPS-induced acute liver failure.
    J Gastroenterol Hepatol. 2024;39:2880-2891.
    >> Share

  79. CHEE NM, Sinnanaidu RP, Chan WK
    Vitamin E improves serum markers and histology in adults with metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024;39:2545-2554.
    >> Share

  80. LI Y, Dai C, Yang H, Zeng H, et al
    Cross-sectional and Mendelian randomization study of fibroblast growth factor 19 reveals causal associations with metabolic diseases.
    J Gastroenterol Hepatol. 2024;39:2872-2879.
    >> Share

    November 2024
  81. GE W, Wang Z, Zhong X, Chen Y, et al
    PLK2 inhibited oxidative stress and ameliorated hepatic ischemia-reperfusion injury through phosphorylating GSK3beta.
    J Gastroenterol Hepatol. 2024 Nov 19. doi: 10.1111/jgh.16815.
    >> Share

  82. JAROENLAPNOPPARAT A, Prasitsumrit V, Ponvilawan B, Waitayangkoon P, et al
    Clostridioides difficile infection increases in-hospital mortality, length of stay, and hospital cost but not 30-day mortality in cirrhotic patients.
    J Gastroenterol Hepatol. 2024 Nov 13. doi: 10.1111/jgh.16807.
    >> Share

  83. ZENG X, Liao Y, Cheng W
    Transient receptor potential channel 6 knockout ameliorates hepatic fibrosis by inhibiting the activation and proliferation of hepatic stellate cells.
    J Gastroenterol Hepatol. 2024 Nov 7. doi: 10.1111/jgh.16802.
    >> Share

  84. ABOONA MB, Danpanichkul P, Chen VL, Rangan P, et al
    Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake.
    J Gastroenterol Hepatol. 2024;39:2456-2463.
    >> Share

  85. LAM LK, Tan JT, Ooi PH, Zhang R, et al
    Effect of metabolic dysfunction-associated steatotic liver disease on BNT162b2 immunogenicity against the severe acute respiratory syndrome coronavirus 2 omicron variant.
    J Gastroenterol Hepatol. 2024;39:2386-2393.
    >> Share

  86. WONGTRAKUL W, Niltwat S, Charatcharoenwitthaya N, Karaketklang K, et al
    Global prevalence of advanced fibrosis in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024;39:2299-2307.
    >> Share

    October 2024
  87. ZHU W, Fan C, Liu B, Qin J, et al
    Therapeutic targets for hepatocellular carcinoma identified using proteomics and Mendelian randomization.
    J Gastroenterol Hepatol. 2024 Oct 30. doi: 10.1111/jgh.16785.
    >> Share

  88. PRINCE DS, Hoque S, Kim C, Maher S, et al
    Cirrhosis in primary practice: many patients remain potentially undiagnosed and are not receiving liver cancer surveillance.
    J Gastroenterol Hepatol. 2024 Oct 24. doi: 10.1111/jgh.16782.
    >> Share

  89. LI Y, Chen L, Li S, Song H, et al
    The m6A reader IGF2BP1 contributes to the activation of hepatic stellate cells through facilitating TUBB4B mRNA stabilization.
    J Gastroenterol Hepatol. 2024 Oct 15. doi: 10.1111/jgh.16765.
    >> Share

  90. ZHANG L, Xu L, Rong A, Cui Y, et al
    Effect of Rab18 on liver injury and lipid accumulation by regulating perilipin 2 and peroxisome proliferator-activated receptor gamma in non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2024;39:2219-2227.
    >> Share

  91. LEOW YW, Chan WL, Lai LL, Mustapha NRN, et al
    LIVERSTAT for risk stratification for patients with metabolic dysfunction-associated fatty liver disease.
    J Gastroenterol Hepatol. 2024;39:2182-2189.
    >> Share

  92. YANG J, Choi WM, Lee D, Shim JH, et al
    Revisiting the steatosis-associated fibrosis estimator score in young Asian subjects with steatotic liver disease and consideration for population variability.
    J Gastroenterol Hepatol. 2024;39:2112-2119.
    >> Share

  93. ALATAS FS, Yamaza T, Matsuura T, Ongko L, et al
    Potential role of stem cells from human exfoliated deciduous teeth in inducing liver regeneration.
    J Gastroenterol Hepatol. 2024;39:2190-2196.
    >> Share

    September 2024
  94. KU JL, Hsu JR, Li YT, Wu LL, et al
    Interplay among IL1R1, gut microbiota, and bile acids in metabolic dysfunction-associated steatotic liver disease: a comprehensive review.
    J Gastroenterol Hepatol. 2024 Sep 29. doi: 10.1111/jgh.16750.
    >> Share

  95. PASSOS PRC, Filho VOC, Noronha MM, Hyppolito EB, et al
    Influence of glucagon-like peptide-1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024 Sep 25. doi: 10.1111/jgh.16752.
    >> Share

  96. HO CT, Tan EH, Lee PC, Su CW, et al
    Reply to "Association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy: concerns to be addressed".
    J Gastroenterol Hepatol. 2024 Sep 19. doi: 10.1111/jgh.16754.
    >> Share

  97. EADIE L, Lo LA, Boivin M, Deol JK, et al
    Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review.
    J Gastroenterol Hepatol. 2024 Sep 3. doi: 10.1111/jgh.16730.
    >> Share

  98. NJEI B, Al-Ajlouni YA, Ameyaw P, Njei LP, et al
    Role of ammonia and glutamine in the pathogenesis and progression of metabolic dysfunction-associated steatotic liver disease: A systematic review.
    J Gastroenterol Hepatol. 2024;39:1788-1808.
    >> Share

  99. KIM D, Manikat R, Wijarnpreecha K, Cholankeril G, et al
    Estimated pulse wave velocity in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality.
    J Gastroenterol Hepatol. 2024;39:1950-1956.
    >> Share

  100. CHEN YT, Chen TI, Yin SC, Huang CW, et al
    Prevalence, proportions of elevated liver enzyme levels, and long-term cardiometabolic mortality of patients with metabolic dysfunction-associated steatotic liver disease.
    J Gastroenterol Hepatol. 2024;39:1939-1949.
    >> Share

    August 2024
  101. HENRY-BLAKE C, Balachandrakumar V, Kassab M, Devonport J, et al
    Lower hepatocellular carcinoma surveillance in metabolic dysfunction-associated steatotic liver disease: Impact on treatment eligibility.
    J Gastroenterol Hepatol. 2024 Aug 27. doi: 10.1111/jgh.16727.
    >> Share

  102. ZHANG X, Chen C, Wang Y, Xu J, et al
    Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation.
    J Gastroenterol Hepatol. 2024 Aug 7. doi: 10.1111/jgh.16693.
    >> Share

  103. WU T, Ye J, Mo S, Ye M, et al
    Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians.
    J Gastroenterol Hepatol. 2024;39:1636-1647.
    >> Share

  104. BANERJEE A, Blinston D, Narain MA
    Inhibition of liver fibrosis by TET1 may be B cell mediated: Supporting evidence from a case of TNFAIP3 deficiency.
    J Gastroenterol Hepatol. 2024;39:1706-1707.
    >> Share

  105. FUKUNISHI Y, Hiraoka A, Tada F, Fukumoto M, et al
    Changes in characteristics of gastroenterology center inpatients in Japan because of rapidly aging society.
    J Gastroenterol Hepatol. 2024;39:1528-1534.
    >> Share

    July 2024
  106. BIAN J, Sang X
    Association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy: Concerns to be addressed.
    J Gastroenterol Hepatol. 2024 Jul 25. doi: 10.1111/jgh.16694.
    >> Share

  107. CHU CS, Chen HP, Lin PH, Cheng CC, et al
    Interleukin-1 receptor 1 deficiency worsens hepatocellular carcinoma, while gemcitabine treatment alleviates the hepatocellular carcinoma-induced increase in intra-hepatic immune cells.
    J Gastroenterol Hepatol. 2024 Jul 15. doi: 10.1111/jgh.16674.
    >> Share

  108. XIN Z, Chen H, Xu J, Zhang H, et al
    Exosomal mRNA in plasma serves as a predictive marker for microvascular invasion in hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 Jul 7. doi: 10.1111/jgh.16677.
    >> Share

  109. NAKASHIMA R, Kitano Y, Okabe H, Tanizaki T, et al
    Rising pseudocysts in the hepatoduodenal ligament caused by a ruptured intraductal papillary mucinous neoplasm with surgical treatment.
    J Gastroenterol Hepatol. 2024 Jul 1. doi: 10.1111/jgh.16669.
    >> Share

  110. MORI K, Akiyama Y, Tanaka M, Sato T, et al
    Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis.
    J Gastroenterol Hepatol. 2024;39:1382-1393.
    >> Share

  111. MALANDRIS K, Papandreou S, Vasilakou D, Kakotrichi P, et al
    Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta-analysis.
    J Gastroenterol Hepatol. 2024;39:1219-1229.
    >> Share

  112. LEE RC, Liang PC, Liang HL, Chen YF, et al
    Multicenter evaluation of the safety and efficacy of selective internal radiation therapy with yttrium-90 resin microspheres in Taiwan: data from the RESIN registry.
    J Gastroenterol Hepatol. 2024;39:1318-1327.
    >> Share

  113. SUGITA H, Nakanuma S, Munesue S, Ishikawa T, et al
    Cilostazol improves the prognosis after hepatectomy in rats with sinusoidal obstruction syndrome.
    J Gastroenterol Hepatol. 2024;39:1413-1421.
    >> Share

    June 2024
  114. SUZUKI T, Matsuura K, Suzuki Y, Okumura F, et al
    Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis.
    J Gastroenterol Hepatol. 2024 Jun 28. doi: 10.1111/jgh.16672.
    >> Share

  115. CHENG J, Yang S, Shou D, Chen J, et al
    FOXO1 induced fatty acid oxidation in hepatic cells by targeting ALDH1L2.
    J Gastroenterol Hepatol. 2024 Jun 25. doi: 10.1111/jgh.16662.
    >> Share

  116. CHATZIPANAGIOTOU OP, Loukas C, Vailas M, Machairas N, et al
    Artificial intelligence in hepatocellular carcinoma diagnosis: a comprehensive review of current literature.
    J Gastroenterol Hepatol. 2024 Jun 23. doi: 10.1111/jgh.16663.
    >> Share

  117. MAUNG ST, Tanpowpong N, Satja M, Treeprasertsuk S, et al
    MRI for hepatocellular carcinoma and the role of abbreviated MRI for surveillance of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 Jun 20. doi: 10.1111/jgh.16643.
    >> Share

  118. MALIK S, Tenorio BG, Moond V, Dahiya DS, et al
    Systematic review of machine learning models in predicting the risk of bleed/grade of esophageal varices in patients with liver cirrhosis: A comprehensive methodological analysis.
    J Gastroenterol Hepatol. 2024 Jun 17. doi: 10.1111/jgh.16645.
    >> Share

  119. HO CT, Fu CC, Tan EC, Kao WY, et al
    The association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy.
    J Gastroenterol Hepatol. 2024 Jun 12. doi: 10.1111/jgh.16640.
    >> Share

  120. WURSTLE S, Schneider T, Karapetyan S, Hapfelmeier A, et al
    LINAS-Score: prognostic model for mortality assessment in patients with cirrhotic liver and infected ascites.
    J Gastroenterol Hepatol. 2024 Jun 5. doi: 10.1111/jgh.16637.
    >> Share

  121. LEE KJ, Moon JS, Lim JG, Huh H, et al
    PARVB and HSD17B13 variants are associated with nonalcoholic fatty liver disease in children.
    J Gastroenterol Hepatol. 2024;39:1172-1182.
    >> Share

    May 2024
  122. HAYASHI M, Abe K, Sugaya T, Takahata Y, et al
    A low baseline serum myostatin concentration is associated with poor clinical outcome in patients with primary biliary cholangitis.
    J Gastroenterol Hepatol. 2024 May 30. doi: 10.1111/jgh.16639.
    >> Share

  123. SUN Z, Guo Y, Xu X, Zhou C, et al
    Hydronidone induces apoptosis in activated hepatic stellate cells through endoplasmic reticulum stress-associated mitochondrial apoptotic pathway.
    J Gastroenterol Hepatol. 2024 May 28. doi: 10.1111/jgh.16635.
    >> Share

  124. SHIN SK, Oh S, Chun SK, Ahn MJ, et al
    Immune signature and therapeutic approach of natural killer cell in chronic liver disease and hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 May 27. doi: 10.1111/jgh.16584.
    >> Share

  125. LIU S, Gou H, Wei H, Chen S, et al
    Cholecystohepatic shunt pathway reduces secondary bile acid accumulation to enhance natural killer T cell-mediated anti-hepatocellular carcinoma immunity.
    J Gastroenterol Hepatol. 2024 May 15. doi: 10.1111/jgh.16548.
    >> Share

  126. KOUNTOURAS J, Zavos C, Vardaka E, Kyrailidi F, et al
    Helicobacter pylori and metabolic syndrome-related adipokines in nonalcoholic fatty liver disease pathophysiology.
    J Gastroenterol Hepatol. 2024 May 9. doi: 10.1111/jgh.16621.
    >> Share

  127. LIM J, Kim JH, Kim SE, Han SK, et al
    Validation of MELD 3.0 in patients with alcoholic liver cirrhosis using prospective KACLiF cohort.
    J Gastroenterol Hepatol. 2024 May 8. doi: 10.1111/jgh.16591.
    >> Share

  128. LEE J, Jin YJ, Shin SK, Kwon JH, et al
    Clinical outcomes of transarterial chemoembolization in Child-Turcotte Pugh class A patients with a single small (
    J Gastroenterol Hepatol. 2024 May 6. doi: 10.1111/jgh.16581.
    >> Share

  129. ENDO K, Kakisaka K, Abe T, Yusa K, et al
    Positive impact of obesity on the prognosis of liver cirrhosis.
    J Gastroenterol Hepatol. 2024 May 3. doi: 10.1111/jgh.16590.
    >> Share

  130. LEE S, Choi J, Park JH, Lim CY, et al
    Dynamic liver volume change in predicting hepatic decompensation and long-term effects of stereotactic body radiation therapy.
    J Gastroenterol Hepatol. 2024 May 2. doi: 10.1111/jgh.16588.
    >> Share

  131. ZHONG W, Xu B, Lu Y, Chang J, et al
    Postoperative adjuvant chemotherapy is important for improving long-term survival in patients with colorectal cancer liver metastases undergoing simultaneous resection.
    J Gastroenterol Hepatol. 2024;39:908-919.
    >> Share

  132. PEI X, Jiang W, Li L, Zeng Q, et al
    Mendelian-randomization study revealed causal relationship between nonalcoholic fatty liver disease and osteoporosis/fractures.
    J Gastroenterol Hepatol. 2024;39:847-857.
    >> Share

  133. MAKRI ES, Evripidou K, Polyzos SA
    Circulating leptin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis.
    J Gastroenterol Hepatol. 2024;39:806-817.
    >> Share

    April 2024
  134. QI S, Wei X, Zhao J, Wei X, et al
    Performance of MAST, FAST, and MEFIB in predicting metabolic dysfunction-associated steatohepatitis.
    J Gastroenterol Hepatol. 2024 Apr 30. doi: 10.1111/jgh.16589.
    >> Share

  135. CAO QH, Liu H, Yan LJ, Wang HC, et al
    Role of hepatitis B core-related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta-analysis.
    J Gastroenterol Hepatol. 2024 Apr 30. doi: 10.1111/jgh.16558.
    >> Share


  136. Retraction: Rami Al Batran, Fouad Al-Bayaty, Mahmood Ameen Abdulla, Mazen M Jamil Al-Obaidi, Maryam Hajrezaei, Pouya Hassandarvish, Mustafa Fouad, Shahram Golbabapour, Samaneh Talaee. Gastroprotective effects of Corchorus olitorius. J Gastroenterol He
    J Gastroenterol Hepatol. 2024 Apr 26. doi: 10.1111/jgh.16551.
    >> Share

  137. GRYZIAK M, Kraj L, Stec R
    The role of tumor-associated macrophages in hepatocellular carcinoma-from bench to bedside: A review.
    J Gastroenterol Hepatol. 2024 Apr 23. doi: 10.1111/jgh.16564.
    >> Share

  138. LOON E, Narvaez-Barbecho C, Ortiz JP, Balderramo D, et al
    Impact of self-reported ancestry on the epidemiology of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 Apr 13. doi: 10.1111/jgh.16578.
    >> Share

  139. LIU Y, Hu Y, Li B, Su R, et al
    Innate lymphoid cell subsets in the pathogenesis of primary biliary cholangitis.
    J Gastroenterol Hepatol. 2024 Apr 12. doi: 10.1111/jgh.16547.
    >> Share

  140. OHAMA H, Hiraoka A, Tada T, Kariyama K, et al
    Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.
    J Gastroenterol Hepatol. 2024 Apr 11. doi: 10.1111/jgh.16553.
    >> Share

  141. CHAN WK, George J
    Metabolic fatty liver syndromes: where do we stand in 2024?
    J Gastroenterol Hepatol. 2024;39:613-614.
    >> Share

  142. PARENTE A, Milana F, Hajibandeh S, Hajibandeh S, et al
    Clinical outcomes after transplantation of domino grafts or standard deceased donor livers: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024;39:620-629.
    >> Share

    March 2024
  143. WANG X, Liu H, Wang Y, Wang P, et al
    Novel protein C6ORF120 promotes liver fibrosis by activating hepatic stellate cells through the PI3K/Akt/mTOR pathway.
    J Gastroenterol Hepatol. 2024 Mar 24. doi: 10.1111/jgh.16538.
    >> Share

  144. SUZUKI K, Yasui Y, Tsuchiya K, Matsumoto H, et al
    Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
    J Gastroenterol Hepatol. 2024 Mar 17. doi: 10.1111/jgh.16532.
    >> Share

  145. BALE G, Kulkarni AV, Padaki NR, Menon PB, et al
    Comparing rare variants versus common in the pathogenesis of nonalcoholic fatty liver disease: a whole exome sequencing approach.
    J Gastroenterol Hepatol. 2024;39:587-595.
    >> Share

    February 2024
  146. SOGABE M, Okahisa T, Kagawa M, Sei M, et al
    Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study.
    J Gastroenterol Hepatol. 2024 Feb 29. doi: 10.1111/jgh.16530.
    >> Share


  147. Correction to "Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis".
    J Gastroenterol Hepatol. 2024 Feb 25. doi: 10.1111/jgh.16529.
    >> Share

  148. TADA T, Kumada T, Hiraoka A, Kariyama K, et al
    mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response.
    J Gastroenterol Hepatol. 2024 Feb 25. doi: 10.1111/jgh.16512.
    >> Share

  149. WANG J, Zhang Y, Ma Y, Zhao S, et al
    TET1 inhibits liver fibrosis by blocking hepatic stellate cell activation.
    J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16443.
    >> Share

  150. BATT NM, Rodrigues B, Bloom S, Sawhney R, et al
    Metabolic-associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy.
    J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16501.
    >> Share

  151. HAHN JW, Lee H, Shin M, Seong MW, et al
    Diagnostic algorithm for neonatal intrahepatic cholestasis integrating single-gene testing and next-generation sequencing in East Asia.
    J Gastroenterol Hepatol. 2024 Feb 7. doi: 10.1111/jgh.16505.
    >> Share

  152. JI PX, Chen YX, Ni XX, Miao Q, et al
    Effect of triggering receptor expressed on myeloid cells 2-associated alterations on lipid metabolism in macrophages in the development of non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2024;39:369-380.
    >> Share

    January 2024
  153. TOYODA H, Tada T, Uojima H, Nozaki A, et al
    Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 Jan 30. doi: 10.1111/jgh.16494.
    >> Share

  154. AMJAD W, Jiang Z, Lai M
    Statin use in cirrhosis and its association with incidence of portal vein thrombosis.
    J Gastroenterol Hepatol. 2024 Jan 25. doi: 10.1111/jgh.16495.
    >> Share

  155. DIAO L, Wang C, You R, Leng B, et al
    Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    J Gastroenterol Hepatol. 2024 Jan 19. doi: 10.1111/jgh.16463.
    >> Share

  156. ZHU J, Xia Y, Liu X, Zhang C, et al
    Preventing variceal rebleeding in cirrhotic patients with portal vein thrombosis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16489.
    >> Share

  157. NIE MT, Wang PQ, Shi PM, Hong XL, et al
    Rifaximin treatment shapes a unique metagenome-metabolism network in patients with decompensated cirrhosis.
    J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16484.
    >> Share

  158. SOGABE M, Okahisa T, Kagawa M, Sei M, et al
    Association of metabolic dysfunction-associated fatty liver disease with gallstone development: A longitudinal study.
    J Gastroenterol Hepatol. 2024 Jan 11. doi: 10.1111/jgh.16483.
    >> Share

    December 2023
  159. GOPAL P, Banerjee D, Karad A, Dandi K, et al
    Gastrointestinal: Congenital portosystemic shunt (Abernathy type 2) with cirrhosis of liver.
    J Gastroenterol Hepatol. 2023 Dec 26. doi: 10.1111/jgh.16456.
    >> Share

  160. CHO SH, Song TJ, Oh D, Park DH, et al
    Endoscopic ultrasound-guided hepaticoduodenostomy versus percutaneous drainage for right intrahepatic duct dilatation in malignant hilar obstruction.
    J Gastroenterol Hepatol. 2023 Dec 18. doi: 10.1111/jgh.16442.
    >> Share

  161. TOSHIDA K, Itoh S, Yoshiya S, Nagao Y, et al
    Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Dec 12. doi: 10.1111/jgh.16441.
    >> Share

  162. HUANG X, Zhou LZ, Feng WJ, Liu YQ, et al
    Circ ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 increases the stability of G9a and ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 messenger RNA through recruiting eukaryotic translation
    J Gastroenterol Hepatol. 2023 Dec 7. doi: 10.1111/jgh.16408.
    >> Share

  163. YANG Y, Liu S, Li H, Liu Y, et al
    The protective effect of Nostoc commune Vauch. polysaccharide on alcohol-induced acute alcoholic liver disease and gut microbiota disturbance in mice.
    J Gastroenterol Hepatol. 2023;38:2185-2194.
    >> Share

  164. TONG C, Halengbieke A, Ni X, Han Y, et al
    Bidirectional relationship between nonalcoholic fatty liver disease and serum creatinine-to-body weight ratio as a proxy for skeletal muscle mass index.
    J Gastroenterol Hepatol. 2023;38:2061-2069.
    >> Share

  165. NARANG M, Shah D, Narang S, Gupta N, et al
    Ultrasound-guided aspiration in addition to antibiotics for treatment of liver abscess in children: A randomized controlled trial.
    J Gastroenterol Hepatol. 2023;38:2070-2075.
    >> Share

    November 2023
  166. SHI L, Feng G, Yang X, Zhang Y, et al
    Potential of PAQosome as a therapeutic target for hepatic fibrosis.
    J Gastroenterol Hepatol. 2023 Nov 28. doi: 10.1111/jgh.16427.
    >> Share

  167. DU S, Cao K, Yan Y, Wang Y, et al
    Developments and current status of cell-free DNA in the early detection and management of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2023 Nov 21. doi: 10.1111/jgh.16416.
    >> Share

  168. ALLAIRE M, Thabut D
    The applicability of Baveno criteria in the setting of hepatocellular carcinoma remains a controversy.
    J Gastroenterol Hepatol. 2023 Nov 21. doi: 10.1111/jgh.16415.
    >> Share

  169. FAROOQ U, Tarar ZI, El Alayli A, Kamal F, et al
    Analyzing the utility of renal replacement therapy to manage hepatorenal syndrome in alcoholic hepatitis without liver transplantation: a nationwide analysis.
    J Gastroenterol Hepatol. 2023 Nov 12. doi: 10.1111/jgh.16388.
    >> Share

  170. SUN J
    Navigating the complex landscape of non-alcoholic fatty liver disease: From genomic associate to the AMPK/mTOR pathways.
    J Gastroenterol Hepatol. 2023;38:1863-1864.
    >> Share

  171. TIAN Y, Wang B
    Unraveling the pathogenesis of non-alcoholic fatty liver diseases through genome-wide association studies.
    J Gastroenterol Hepatol. 2023;38:1877-1885.
    >> Share

  172. WANG Y, Huang Y, Zheng T, Sun C, et al
    Gastrointestinal hospitalization during COVID-19 pandemic in the United States: Analysis of a nationwide inpatient sample.
    J Gastroenterol Hepatol. 2023;38:1971-1979.
    >> Share

  173. TAKAHASHI A, Takahata Y, Kokubun M, Anzai Y, et al
    Association between equol and non-alcoholic fatty liver disease in Japanese women in their 50s and 60s.
    J Gastroenterol Hepatol. 2023;38:1958-1962.
    >> Share

  174. MARCONDES-DE-CASTRO IA, Reis-Barbosa PH, Marinho TS, Aguila MB, et al
    AMPK/mTOR pathway significance in healthy liver and non-alcoholic fatty liver disease and its progression.
    J Gastroenterol Hepatol. 2023;38:1868-1876.
    >> Share

    October 2023
  175. QUAN Y, Shou D, Yang S, Cheng J, et al
    Mdivi1 ameliorates mitochondrial dysfunction in non-alcoholic steatohepatitis by inhibiting JNK/MFF signaling.
    J Gastroenterol Hepatol. 2023 Oct 15. doi: 10.1111/jgh.16372.
    >> Share

  176. OH JH, Saeed WK, Kim HY, Lee SM, et al
    Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis.
    J Gastroenterol Hepatol. 2023 Oct 9. doi: 10.1111/jgh.16368.
    >> Share

  177. GIRI S, Singh A, Kolhe K, Kale A, et al
    Reply: Portal vein thrombosis in cirrhosis: exploring the uncharted waters.
    J Gastroenterol Hepatol. 2023 Oct 7. doi: 10.1111/jgh.16378.
    >> Share

  178. SHOU D, Luo Q, Tang W, Cao C, et al
    Hepatobiliary and pancreatic: Multi-donor fecal microbiota transplantation attenuated high-fat diet-induced hepatic steatosis in mice by remodeling the gut microbiota.
    J Gastroenterol Hepatol. 2023 Oct 3. doi: 10.1111/jgh.16359.
    >> Share

  179. ITO T, Morooka H, Takahashi H, Fujii H, et al
    Identification of clinical phenotypes associated with poor prognosis in patients with nonalcoholic fatty liver disease via unsupervised machine learning.
    J Gastroenterol Hepatol. 2023;38:1832-1839.
    >> Share

  180. VAZ K, Kemp W, Majeed A, Lubel J, et al
    Non-alcoholic fatty liver disease prevalence in Australia has risen over 15 years in conjunction with increased prevalence of obesity and reduction in healthy lifestyle.
    J Gastroenterol Hepatol. 2023;38:1823-1831.
    >> Share

  181. RONG L, Ch'ng D, Jia P, Tsoi KKF, et al
    Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023;38:1682-1694.
    >> Share

  182. TAKAHASHI Y, Seko Y, Yamaguchi K, Takeuchi K, et al
    Gamma-glutamyl transferase predicts pemafibrate treatment response in non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2023;38:1743-1749.
    >> Share

    September 2023
  183. KANG SH, Kim MY, Han SK, Baik SK, et al
    Subclinical diabetes confirmed by 75-g OGTT influence on the prognosis of decompensated cirrhosis.
    J Gastroenterol Hepatol. 2023 Sep 11. doi: 10.1111/jgh.16327.
    >> Share

  184. HIRATA K, Yamamoto Y, Hatanaka K, Kinoshita K, et al
    Hepatobiliary and pancreatic: Tiny pigmented intra-hepatic ducts stones as the cause of jaundice and liver failure.
    J Gastroenterol Hepatol. 2023 Sep 8. doi: 10.1111/jgh.16350.
    >> Share

  185. MURAKAMI S, Uchida T, Imamura M, Suehiro Y, et al
    Correlation between serum pro-inflammatory cytokine levels and the prognosis of the patients with acute liver failure.
    J Gastroenterol Hepatol. 2023;38:1637-1646.
    >> Share

  186. HAN E, Chun HS, Lee YH, Lee JS, et al
    MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
    J Gastroenterol Hepatol. 2023;38:1598-1609.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016